Drugs for disorders of the blood or the extracellular fluid (A61P7)

A   Human necessities(312083)
A61P7                 Drugs for disorders of the blood or the extracellular fluid(1258)
Combined administration of gdf traps and erythropoetin receptor activators for increasing content of erythrocytes // 2642302
FIELD: biotechnology.SUBSTANCE: method of treatment comprises of administration to the patient of an isolated polypeptide including the amino acid sequence of SEQ ID NO: 28.EFFECT: invention makes it possible to effectively increase the contents of erythrocytes in patients.17 cl, 22 dwg, 19 ex

Thrombin-binding molecules of antibodies and their application // 2642276
FIELD: pharmacology.SUBSTANCE: isolated antibody molecule, specifically binding to the thrombin exosite area 1, and an antigen-binding fragment of said antibody, are provided. The use of the antibody molecule in the manufacture of medicaments is considered. A pharmaceutical composition is described as well as a method for treating a thrombin-mediated condition.EFFECT: use in the treatment of diseases associated with thrombin.25 cl, 22 dwg, 4 tbl
Partly saturated nitrogen-containing heterocyclic compound // 2641291
FIELD: chemistry.SUBSTANCE: invention relates to a compound of the formula (I'), (wherein W represents the formula -CR11R12CR13R14-; R11 represents a hydrogen atom, a fluorine atom, C1-4 alkyl or phenyl; R12 represents a hydrogen atom, a fluorine atom or C1-4 alkyl; provided that R11 and R12, together with the adjacent carbon atom, optionally form C3-8 cycloalkane or tetrahydropyran; R13 represents a hydrogen atom, a carbamoyl, C1-4 alkyl (C1-4 alkyl is optionally substituted by one group selected from the group consisting of hydroxy, C1-3 alkoxy and di-C1-3 alkylamino), halo-C1-4 alkyl, phenyl, pyridyl, benzyl or phenethyl; R14 represents a hydrogen atom, C1-4 alkyl or halogen-C1-4 alkyl; Y represents a single bond or C1-6 alkanediyl (C1-6 alkanediyl is optionally substituted by one hydroxy group and one of the carbon atoms in C1-6 alkanediyl is optionally substituted by cycloalkpropane-1,1-diyl); R2 represents a hydrogen atom, C1-6 alkyl, C3-8 cycloalkyl {C3-8 cycloalkyl is optionally substituted by one or two groups that are the same or different and are selected from the group consisting of C1-6 alkyl (C1-6 alkyl is optionally substituted by one phenyl group), phenyl (phenyl is optionally substituted by one halogen atom), C1-6 alkoxy [C1-6 alkoxy is optionally substituted by one group selected from the group consisting of C3-8 cycloalkyl, phenyl (phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C1-6 alkyl) and pyridyl (pyridyl is optionally substituted by one halogen atom)], C3-8 cycloalkoxy, phenoxy (phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C1-6 alkyl, C3-8 cycloalkyl and halogen-C1-6 alkyl) and pyridyloxy (pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C1-6 alkyl, C3-8 cycloalkyl and halogen-C1-6 alkyl)}, phenyl (phenyl is optionally substituted by one to three groups that are the same or different and which are selected from the group of α3 substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl [pyrazolyl is optionally substituted by one or two groups that are the same or different and are selected from the group consisting of C1-6 alkyl and phenyl (phenyl optionally substituted by one C1-6 alkyl)], imidazolyl [imidazolyl is optionally substituted by one or two groups that are the same or different and are selected from the group consisting of C1-6 alkyl and phenyl], isoxazolyl [isoxazolyl is optionally substituted by one phenyl group (phenyl is optionally substituted by one halogen atom)], oxazolyl [oxazolyl is optionally substituted by one or two groups that are the same or different and which are selected from the group consisting of C1-6 alkyl and phenyl], thiazolyl [thiazolyl is optionally substituted by one or two groups that are the same or different and which are selected from the group consisting of C1-6 alkyl, phenyl and morpholino], pyridyl (pyridyl is optionally substituted by one or two groups that are are the same or different and are selected from the group of α5 substituents), pyridazinyl [pyridazinyl is optionally substituted by one C1-6 alkoxy (C1-6 alkoxy is optionally substituted by one C3-8 cycloalkyl group)], pyrimidinyl [pyrimidinyl is optionally substituted by one group selected from the group consisting of halogen-C1-6 alkyl, C3-8 cycloalkyl, phenyl and phenoxy (phenoxy is optionally substituted by one C1-6 alkyl)], pyrazinyl [pyrazinyl is optionally substituted by one group selected from the group consisting of C1-6 alkoxy (C1-6 alkoxy is optionally substituted by one C3-8 cycloalkyl), and phenoxy (phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C1-6 alkyl and C3-8 cycloalkyl)], benzothiophenyl, quinolyl, methylenedioxyphenyl (methylenedioxyphenyl is optionally substituted by one or two fluorine atoms), azetidinyl (azetidinyl is optionally substituted with one pyrimidinyl group), piperidinyl (piperidinyl is optionally substituted by one group selected from the group consisting of pyrimidinyl, phenyl-C1-3 alkyl, C3-8 cycloalkyl-C1-3 alkylcarbonyl and phenyl-C1-3 alkoxycarbonyl) or the following formula (I") -CONR5CH2-R6 (I") [wherein in formula (I") R5 represents a hydrogen atom or C1-3 alkyl and R 6 is phenyl (phenyl is optionally substituted by one group selected from the group consisting of a halogen atom, halogen-C1-6 alkyl and phenyl)], Y4 represents C1-4 alkanediyl; R3 represents a hydrogen atom or methyl; R4 represents -COOH or -CONHOH).EFFECT: compound has a superior PHD2 inhibitory effect.16 cl, 28 tbl, 11 ex
ethod for prevention of venous thromboembolia in patients with cervical cancer // 2641058
FIELD: medicine.SUBSTANCE: for prevention of venous thromboembolism in patients with cervical cancer, a patient receives low molecular weight heparins (LMWH) in prophylactic doses considering the risk factors. LMWH dose is prescribed from the first day of hospitalization considering the drug recalculation factor depending on the stage of disease and tumour histological subtype: at stage I of cervical cancer with unchanged coagulogram, a prophylactic LMWH dose with a coefficient equal to 1 is prescribed, and in the presence of high thrombosis in this group of patients, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed; for patients with stage II squamous cell cervical cancer, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed, and for stages III and IV, prophylactic LMWH dose with a coefficient of 1.5 is prescribed; for patients with stage II cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.5; for patients with stages III and IV cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.75 is prescribed.EFFECT: invention allows to prevent development of complications, extend and improve the quality of life of patients undergoing surgery for cervical cancer.5 tbl
Complex compounds of ferric iron for treatment and prevention of symptoms of iron deficiency and iron deficiency anemia // 2641030
FIELD: pharmacology.SUBSTANCE: group of inventions refers to a complex compound of ferric iron or its pharmaceutically acceptable salt, containing at least one formula ligand, drugs and compositions containing a complex compound of ferric iron.EFFECT: implementation of the invention will provide a therapeutically active substance with good activity, a high degree of iron utilisation, stability and sufficient solubility.16 cl, 4 tbl, 21 ex
Hydrochlorides of 1-alkyl-3-methyl-8-piperazino-7-(tiethanyl-3)xanthine showing antithrombotic effect by blocking gp iib-iiia platelets receptors // 2640579
FIELD: pharmacology.SUBSTANCE: invention relates to 1-alkyl-3-methyl-8-piperazino-7-(tiethanyl-3)xanthine hydrochlorides of the general formula: Ia-c, where R=CH2-CH=CH2 (Ia), C3H7-iso (Ib), C5H11-h (Ic).EFFECT: increased antithrombotic effect by blocking the GP IIb-IIIa platelet receptors.5 cl, 2 tbl, 5 ex
eans with systemic hemostatic effect // 2640131
FIELD: pharmacology.SUBSTANCE: application of calcium bis(2-aminoethane-1-sulfonate) as a means of systemic hemostatic effect is proposed.EFFECT: application of the invention extends the arsenal of biologically active substances, including those with a systemic hemostatic effect; the compound exhibits an effective hemostatic effect due to proaggregant activity as compared to ethamylate.2 tbl
ulti-substituted aromatic compounds as thrombin inhibitors // 2639876
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the formula: , and also to pharmaceutical compositions and methods for treatment and prevention of a disease such as thrombotic one.EFFECT: new compounds capable of inhibiting the protease activity of thrombin.15 cl, 3 tbl, 85 ex
ethod for prevention and treatment of iron deficiency anemia of calves under conditions of arid zones // 2639771
FIELD: veterinary medicine.SUBSTANCE: method includes introduction of iron-dextrane preparation Sedimin-Se + IM on day 5-6 of life in a dose of 5 ml, and then immediate intramuscular injection of Hidropepton in a dose of 5 ml.EFFECT: method provides prevention and treatment of iron-deficiency anaemia, improved antioxidant activity of blood serum of calves, decreased free radical oxidation under conditions of arid zones.1 cl

Process for low molecular weight heparin preparation // 2639574
FIELD: pharmacy.SUBSTANCE: group of inventions relates to a method for calcium nadroparin preparation, wherein heparin is dissolved in water, sodium nitrite is added and pH is adjusted to 2-3 by treatment with hydrochloric acid, the solution is kept until nitrite disappearance, and pH is then adjusted to 9-11 by hydroxide sodium addition and then sodium borohydride is introduced into the solution. The group of inventions also relates to calcium nadroparin, obtained by this method, calcium nadroparin application for treatment of diseases requiring anticoagulation. The group of inventions provides a quantity of the low molecular weight fraction (below 2000 Da) of max. 15% of the total fraction 2000-8000 Da and less than 2000 Da.EFFECT: method cost reduction.5 cl, 5 ex, 1 dwg
ethod for treatment of heavy liver lesion with posttraumatic coagulopathy // 2639422
FIELD: medicine.SUBSTANCE: right gastro-omental vein is excised and catheterized, through which fresh frozen plasma and platelet concentrate in a ratio of 1:1 or fresh platelet-rich plasma is transfused into the portal vein system with additional administration of 1 g tranexamic acid for 10 minutes and further administration every 8 hours for 1 g till hyperfibrinolysis reduction. Treatment is carried out under the control of thromboelastography, aggregation, APTT, PT, MHO and fibrinogen level.EFFECT: method allows to achieve maximum hemostatic effect in the wound, to correct the key pathogenetic links of post-traumatic coagulopathy and to reduce the risk of early and distant complications.1 cl
Hemostatic coating in form of sponge or film (versions) // 2639379
FIELD: pharmacology.SUBSTANCE: invention is a hemostatic coating in the form of a sponge or film containing a base and an active substance zeolite, characterized by containing sodium alginate, a plasticizer and water as the base, and natural zeolite (Na2+, K2+)O⋅Al2O3⋅8SiO2⋅10H2O as an active substance, and the components in the hemostatic coating are in a certain ratio, in wt %.EFFECT: expanded assortment of hemostatic sponges and films with pronounced hemostatic action and a significant decrease in the temperature of tissues at the place of agent contact with the wound surface.4 cl, 25 ex
Benzo[d]isoxazole derivatives and their application // 2638155
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the linker L1 is selected independently and represents -CH2-, -NH-, -O- or -S-; R1 is selected independently and is hydrogen, halogen, -C1-3-alkyl, partially or fully halogenated -C1-3-alkyl, -CN, -OH, -O-C1-3-alkyl, -NH2, -NHC1-3-alkyl, -N (C1-3-alkyl) C1-3-alkyl, -C1-3-alkyl-NH2, -C1-3-alkyl-NH-C1-3-alkyl, -C1-3-alkyl-N(C1-3-alkyl)C1-3-alkyl or a 5-membered heteroaryl ring containing 1 to 4 N atoms and 0 to 1 S atom; R1 group contains 0-2 R4 substituents; R2 is selected independently and is halogen, partially or fully halogenated -CH3 or -OCH3; R3 is selected independently and is hydrogen or halogen; R4 is selected independently and is halogen or C1-3-alkyl; A cycle is selected independently and represents phenyl, a 5-6 membered heteroaryl ring containing 1 to 2 N atoms; A cycle contains 0-1 R5 substituent and 0-2 R6substituent; R5 is selected independently and is phenyl; 5-9 membered heteroaryl containing 1 to 2 N atoms and 0 to 1 S or O atom, 5-6 membered cycloalkyl or 5-6 membered heterocycle containing 1 to 2 N atoms, 0 to 1 S or O atoms; R5 contains 0-2 R'6substituents; R6 and R'6 are selected independently and represent -OH, -C1-3-alkyl, -C(O)OH, -C(O)NH2, -NHC(O)H, -NHC(O)C1-3-alkyl, -C1-3-alkyl-NHC(O)H, -C1-3-alkyl-NHC(O)C1-3-alkyl, -NHC(O)OH, -C1-3-alkyl-NHC(O)OH, -NH2, -NHC1-3-alkyl, -N(C1-3-alkyl)C1-3-alkyl, -C1-3-alkyl-NH2, -C1-3-alkyl-NHC1-3-alkyl, -C1-3-alkyl-N(C1-3-alkyl)C1-3-alkyl, -CN, halogen, -S(O)2NH2, a 5-6 membered saturated, unsaturated or partially saturated heterocycle containing 1 to 4 N atoms, 0 to 1 atom S; R6 and R'6 contain 0-2 R7 substituents; R7 is selected independently and is = O, -C1-3-alkyl, -NH2, -NHC1-3-alkyl, -N (C1-3-alkyl) C1-3-alkyl, -C1-3-alkyl-NH2, -C1-3-alkyl-NHC1-3-alkyl, -C1-3-alkyl-N(C1-3-alkyl)C1-3-alkyl, -OH, -OC1-3-alkyl, -C1-3-alkyl-OH, -C1-3-alkyl-O-C1-3-alkyl or halogen. The compounds of the invention are intended to be used as inhibitors of the coagulation factor XIa in blood or plasma, as well as for preparation of a pharmaceutical composition for treatment and/or prevention of a condition of a mammal characterized by undesirable thrombosis. A pharmaceutical composition for treatment and/or prevention of a condition of a mammal characterized by undesired thrombosis comprises an effective amount of a compound of the invention and at least one pharmaceutically acceptable excipient.EFFECT: increased efficiency of derivatives.9 cl, 5 ex
ethod for reduction of limbs necrosis development risk in case of cold injury // 2637086
FIELD: medicine.SUBSTANCE: method involves application of a heat-insulating dressing to the affected limbs, medical and infusion therapy. At that, in the pre-active period, for index of nail phalanges interstitial thermometry below 12-14°C, intravenous injections of 20-60 mcg of vasaprostan, diluted in 250 ml of physiological solution are performed.EFFECT: minimum risk of limbs necrosis development in case of cold injury.3 cl
Substituted pyrrolidines as xia factor inhibitors for thromboembolic diseases treatment // 2636050
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of the general formula , their pharmaceutically acceptable salts, pharmaceutical compositions containing the said compounds.EFFECT: compounds of general formula I are XIa factor inhibitors and are suitable for thromboembolic diseases prevention or treatment.22 cl, 1 tbl, 115 ex

Procoagulant peptides, their derivatives and their application // 2635510
FIELD: medicine.SUBSTANCE: group of inventions includes a hemostatic material comprising a peptide having the sequence of SEQ ID NO: 1 or its sequence of amino acid analogs and a framework where the said framework is a natural gelatin polymer, wherein the gelatin comprises an absorbable hemostatic powder matrix, a sponge matrix, a pasty matrix , a gel matrix or combinations thereof, and the said gelatin is cross-linked and has the form of particles with a liquid carrier, as well as a material for tissue healing anal and a method for hemostatic treatment or tissue healing at the wound site, comprising formation of a hemostatic material or tissue healing material of a similar composition and application of a hemostatic material or tissue healing material to the wound site.EFFECT: expanded arsenal of technical means of hemostatic purpose, which can successfully work in heparinized blood.33 cl, 8 dwg, 1 tbl, 10 ex

Hemostatic material, hemostatic means and material based thereon // 2635465
FIELD: medicine.SUBSTANCE: material comprising a hemostatic agent O,O'-dipalmitoyl chitosan or a salt thereof and one or more bioadhesive neutral substances are described.EFFECT: increased hemostatic activity of modified chitosan, hydrophobically modified chitosan, high water solubility, increased hemostatic properties of the hemostatic material based on modified chitosan, expansion of the hemostatic arsenal.28 cl, 7 tbl, 1 dwg, 11 ex
Drug with spasmolithic, diuretic and lithiolic action // 2635459
FIELD: pharmacology.SUBSTANCE: agent containing belladonna alkaloids, tincture of European madder, magnesium salicylate, a mixture of essential oils with a set of active substances, salicylic acid, linoleic and linolenic acids, ethanol and castor oil is proposed, wherein the substance contains the sum of belladonna alkaloids, recalculated for hyoscyamine as belladonna alkaloids, eucalyptus essential oil, anise essential oil and fennel essential oil as essential oils, and 1,8-cineole eucalyptus essential oil as a biologically active substance with a certain content of the ingredients.EFFECT: pronounced therapeutic effect in pain elimination and excretion of urinary stones, pronounced anti-inflammatory and diuretic effects.3 ex
Drug with litholithic, diuretic and anti-inflammatory action // 2635196
FIELD: pharmacology.SUBSTANCE: preparation containing a tincture of European madder root, magnesium salicylate, essential oils with a set of active substances, ethyl alcohol and vegetable oil is proposed, the composition further comprises a mixture of linoleic and linolenic acids, castor oil as a vegetable oil, eucalyptus essential oil, anise essential oil and fennel essential oil as essential oils, and 1,8-cineole eucalyptus essential oil as a biologically active substance of essential oils a at certain ratio of the composition ingredients.EFFECT: pronounced therapeutic effect in destruction and excretion of urinary stones, pronounced anti-inflammatory and diuretic effects.2 cl, 4 ex
ethod for endoscopic treatment of ulcerous gastroduodenal bleeding // 2633588
FIELD: medicine.SUBSTANCE: combination of powdered haemostatic agents and a biologically active granular sorbent are used topically. First, powdered lyophilizate NovoSeven and zhelplastan are applied on the bleeding ulcerous defect with an insufflator, in equal quantities of 0.1 g each, from a distance of 1.0 cm from the bleeding defect, and then 0.3 g of diovin is insufflated from a distance of 1.5 cm from the ulcerous surface.EFFECT: method allows to increase hemostasis reliability and reduce the time of treatment.1 tbl
Peroral dabigatran etexilate pharmaceutical compositions // 2633482
FIELD: pharmacology.SUBSTANCE: composition comprises particulate mix, where a) the first particulate type comprises the dabigatran etexilate in the form of the free base or in the form of its pharmaceutically acceptable salts, polymorphs, solvates or hydrates and which does not have acids; and b) the second particulate type comprises at a minimum one pharmaceutically acceptable organic acid, where at a minimum one particulate type is encased in an outer protection sheathe. The composition is destined for the reduction of the stroke and the systemic embolism risk in patients with the nonvalvular atrial fibrillation and/or for the preventive measures for the venous thromboembolic complication in adult patients that had a surgical operation on elective total hip replacement or the surgical operation on total knee arthroplasty.EFFECT: implementation of the invention allows to get the composition, which differs by fast dissolution and significant bioactivation.18 cl, 3 ex, 11 tbl
ethod for operative hemostasis in acute hardly accessible epidural bleedings from damaged veins, fractures of cranial vault and base and subsequent postoperative supervision // 2633299
FIELD: medicine.SUBSTANCE: epidural hematoma is removed, then the dura mater is pierced and liquid is injected thereunder. At that, a puncture with an insulin needle is performed at an angle of approximately 30-40 degrees to the shell surface, its outer sheet is pierced, then the needle tip is slightly raised. The raised area is grasped with an anatomic tweezers and the insulin needle is further injected under the shell. Physiological solution containing 1-2 ml of cyanocobalamin is then injected into the subdural space in a volume sufficient to completely expand the dura mater and tightly adhere to the edges of the bone defect. Then the insulin needle is removed and an epidural catheter is installed through the hole in the dura mater, the height of the liquid column in which indicates the liquid level under the shell. When the shell stress on the catheter is relaxed, an additional volume of physiological solution containing cyanocobalamin is injected.EFFECT: reduced frequency of hemorrhagic complications decreases, reduced operating injury of skull bones decreases, prevention of the development of the trepanized patients syndrome, minimized risk of hematoma recurrence and the best conditions for subsequent skull plasty are provided, while the hard shell is adapted to the edge of the bone defect.1 ex
ethod for reduction of frequency of intraventricular hemorrhage in newborn in case of early preterm delivery, complicated by non-progressing placental abruption // 2632711
FIELD: medicine.SUBSTANCE: from the first minutes, tranexamic acid therapy is provided during admission to the hospital on 25(0)-27(6) weeks of pregnancy for not progressing placental abruption. Hemostatic therapy for patients is performed in the absence of indications for emergency delivery. Hemostatic therapy with tranexamic acid in case of massive (acute) bleeding is prescribed intravenously dropwise for 250-500 mg at a rate of 5-10 mcg/min - 3-4 times a day. The maximum daily dose is 1000-2000 mg/day. Treatment is carried out until the bleeding stops completely, average - 3-4 days. Supportive therapy is prescribed per os 500 mg 3-4 times a day. The maximum daily dose is 1.5-2.0 g, with an average of 3-4 days.EFFECT: decrease in the frequency of intraventricular hemorrhage in a newborn in case early premature delivery at certain time complicated by non-progressive placental abruption.3 ex
ethod for prevention of cerebral vascular cramp in case of nontraumatic subarachnoidal hemorrhages due to aneurism rupture in brain vessels // 2632622
FIELD: medicine.SUBSTANCE: prior to aneurysm clipping, a lumbar drainage is installed, and after clipping, arachnoid dissection is performed and blood clots are removed. The following cisterns are opened: lateral cleft, ipsilateral carotid, chiasmatic, interpeduncular, contralateral carotid and terminal plate cisterns. Then, the terminal plate of the third ventricle is opened, cistern drainage is installed, lumbar drainage is opened, the liquor is withdrawn and the physiological solution is simultaneously introduced into the cistern drainage. Then the lumbar drainage is blocked and Forteplaze is injected into the cistern drainage. The surgical wound is sutured, the spinal fluid is sanitized. 6 hours after the intraoperative administration of Fortepaze, CT scannig of brain is performed and, in the absence of disturbances, Fortepaze is injected once again through the cistern drainage port.EFFECT: reduction of postoperative complications.5 cl, 4 dwg

ethods and application of tissue culture systems ex vivo // 2631807
FIELD: biotechnology.SUBSTANCE: method involves implantation of a microfluidic device that contains a cell growth chamber, an open port, as well as a demineralized bone powder and bone morphogenetic protein, into the subject for 4 weeks or more, resulting in bone marrow tissue formation. Thereafter, the said microfluidic device with the formed tissue contained therein is recovered from the subject. Further, liquid perfusion to the bone marrow tissue is provided to maintain the bone marrow tissue ex vivo. Microfluidic device implantation may be subcutaneous, intraperitoneal or intramuscular.EFFECT: invention allows to obtain bone marrow tissue that will preserve ex vivo functioning.8 cl, 21 dwg, 9 ex
Highly-dispersive emulsion based on perfluororganic compounds with gas transportation properties // 2631608
FIELD: pharmacology.SUBSTANCE: emulsion contains a base in the form of a perfluoroorganic compound, namely a mixture of oxapperfluoroalkyl bromides of the formula: C2F5O-[CF2CF(CF3)O]n-CF2CF2Br, where n is 1 to 5, the specific gravity is 1.78-1.81 g/cm3, boiling point at atmospheric pressure is not more than 142°C, an emulsifying-stabilizing additive in the form of a block copolymer of ethylene oxide and propylene oxide with a molecular weight of 6000-13000 Da, a nonionic surfactant in the form of fluoroaliphatic ether with a density of 1.1-1.17 g/cm3, a co-emulsifier with stabilizing properties based on phospholipid and physiological solution, with the following ratio of components in the emulsion, vol. %: basis 4.5-45.0; emulsifying-stabilizing additive 0.2-8.0; fluoroaliphatic ether 10-3-10-2; co-emulsifier 0.05-0.50; physiological solution the rest.EFFECT: technically and environmentally safe manufacturing technology, high stability under different temperature conditions, required dynamic oxygen capacity.6 cl, 1 tbl, 3 ex
etadihol® - liquid and gel nanolartical preparations // 2631600
FIELD: pharmacology.SUBSTANCE: group concerns the water-gel composition of the inverse agonist VDR, which has the water properties, for the treatment of diseases associated with VDR, where the inverse VDR agonist is a polycosanol, the composition contains polycosanol in the form of nanoparticles in a concentration of 0.5-1 wt %, water-soluble polymer - carbopol in a concentration of 0.5-3 wt %, water, the composition is nano-gel. This composition is used to treat skin diseases.EFFECT: prevention of unwanted side effects of vitamin D in the treatment of skin diseases, increasing the therapeutic effect.5 cl, 5 ex, 57 tbl, 15 dwg
ethod for emergency bleaching and blood crust removal from skin in place of squeezed out acne // 2631593
FIELD: cosmetology.SUBSTANCE: invention is a method of emergency bleaching and blood crust removal from the skin in the place of the squeezed out acne, comprising introduction of a solution of 3% hydrogen peroxide, characterized by additional content of 10% sodium hydrogen carbonate, the solution is pre-applied to a gauze swab area up to the through impregnation, after which the moistened portion of the swab is applied to the selected skin area, pressed firmly against it by the index finger of the dominant hand and moved in the pressed state over the skin surface, wiping by continuous movements of the finger pad for no longer than 5 seconds, after which the swab is removed, the skin under it is visually evaluated, and if traces of pus and blood remain, the swab is applied repeatedly until the pigmented spot acquires the size and shape of the mouth of the wound that appeared at the site of the squeezed out acne.EFFECT: invention provides emergency sanitation, reduction in the pigmented spot area and bleaching of the skin surface at the site of the squeezed out acne under conditions excluding skin coating with pigmented substances and films.1 ex
ethod for whitening of sore under nail // 2631592
FIELD: medicine.SUBSTANCE: invention is a method of whitening of a sore under the nail, which includes lighting of the selected body portion with a flow of white scattered light, visual determination of sore localization and size under the nail, careful nail piercing in a convex spot with a hot needle, releasing blood from under the nail through the formed hole, introduction of a drug solution using an injection syringe connected to an injection needle, at a temperature of 37-42°C in a volume that provides tissue bleaching, characterized by nail piercing to the hematoma cavity, the hole is formed with a diameter exceeding the outer diameter of the injection needle working end, the working end of which is made of blunt elastic material, the blood is discharged by squeezing the nail and the pad with an open hole in the nail with a pressure vector directed perpendicular to the nail plane in the hematoma projection, the needle working end is introduced into the formed hole, the solution is used consisting of 3% hydrogen peroxide and 10% sodium bicarbonate, the solution is injected under the nail after blood removal, the solution is injected under control of the nail colour, until whitening of the subungual hematoma is complete.EFFECT: invention provides emergency blood removal from the cavity of the subungual hematoma and fast bleaching of blood under the fingernail under conditions that exclude post-injection bleeding, inflammation, bloody tissue imploding, development of post-injection bruising and nail pigmentation.1 ex
Compounds // 2630677
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of the general formula ,where Cyc1 is imidazolyl or triazolyl; Cyc2 is phenyl; Cyc3 is phenyl or 5-10 membered heteroaryl containing 1 heteroatom selected from S and N; R1 is halogen; s is equal to 0 or 1, R2 is hydrogen; R3 is hydrogen, C1-8 alkyl or C1-8 alkyl which is substituted by a group selected from pyridyl or -OC1-8 alkyl; Y is N or C (R5); R4 is hydrogen or C1-4 alkyl; R5 is hydrogen or halogen; or R3 and R4 can be taken together to form C2 alkylene; where one carbon of the alkylene chain can be replaced by sulfur; R6 is C1-8 alkyl, Cyc10, halogen or Cyc10 substituted by halogen or cyano, wherein Cyc10 is a 5-membered heteroaryl containing 3-4 nitrogen atoms; m is equal to 2, where each R6 can be the same or different; R7 is halogen, -NH2, -COOR48, -NHC (O) O-C1-8 alkyl, -NHC (O) O-C1-4 alkylene-OC1-8 alkyl; R48 is hydrogen or C1-8 alkyl; n is equal to 1 or 2, where n is an integer 2, each R7 can be the same or different; and R62 is hydrogen, their pharmaceutically acceptable salts or solvates thereof.EFFECT: compounds are factor XIa inhibitors, so they can be used to prevent or treat thromboembolic diseases.15 cl, 3 tbl, 927 ex

Hemostatic powders of oxided regenerated cellulose and methods of their production // 2629199
FIELD: chemistry.SUBSTANCE: invention relates to a hemostatic material containing compressed powder of oxidized regenerated cellulose (ORC) produced by grinding in a ball mill. The ORC powder has a bulk density after compaction of, at least, 0.45 g/cm3, fluidity of, at least, 7.5 cm/s. The powder particles have an average size of 1.75 mcm to 116 mcm with a median size of 36 mcm and an average proportionality factor of 1 to 18. The present invention further relates to a method for producing the hemostatic material, a hemostatic paste and the method for treating a wound by applying a hemostatic powder to the patient's wound and/or therein.EFFECT: powder of oxidized regenerated cellulose of the invention is characterized by good adherence, flowability over the tissue and ensures satisfactory placement of powder during surgical procedures.10 cl, 8 dwg, 5 tbl, 9 ex
ethod for coagulopatic bleeding prevention during cesarean section // 2629040
FIELD: medicine.SUBSTANCE: to prevent bleeding during caesarean section, when performing a cut of the anterior abdominal wall during caesarean section, 10 ml of 10% calcium gluconate solution and 10 ml of tranexamic acid containing 1 gram of dry matter are subsequently injected into a peripheral vein.EFFECT: method provides prevention of coagulopathic bleeding with a decrease in perioperative blood loss in patients at risk of such bleeding.8 tbl, 6 ex
Hemostatic sponge and method of its production // 2628809
FIELD: pharmacology.SUBSTANCE: group of inventions is a hemostatic sponge containing a freeze-dried substrate and active substance, characterized in that it contains sodium alginate as the base, and as an active ingredient fibrin monomer with the following ratio of the components in the final aqueous solution in the volume per 1 litre in wt %: Sodium alginate - 0.1-8.0, Fibrin-monomer - 0.01-0.5, as well as a method for obtaining a hemostatic sponge.EFFECT: expansion of the assortment of hemostatic sponges and can be used to stop bleeding in surgical practice, in combat situations, in the aftermath of mass catastrophes and terrorist acts, and in combat situations.4 cl, 13 ex
Treatment of coagulation disease by administration of recombinant vwf // 2628537
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.29 cl, 5 ex, 22 dwg, 34 tbl
Hemostatic sponge (versions) // 2627855
FIELD: medicine.SUBSTANCE: invention is a hemostatic sponge containing a base and iron salts as an active substance, characterized by the base and active substance being freeze-dried, while the sponge contains sodium alginate as the base, and iron sulfate as the active ingredient, the components in the sponge are in a certain ratio in the final aqueous solution, in the volume of 1 litre in %.EFFECT: expanded assortment of hemostatic sponges with pronounced hemostatic action and exclusion of direct adverse effect of the active substance on the wound surface and surrounding tissues due to the pharmacological form of the sponge.4 cl, 37 ex
Agent with antithrombotic activity // 2627435
FIELD: pharmacology.SUBSTANCE: antithrombotic agent based on sulfated cellulose material is cellulose sulphate with a molecular weight of 116000 daltons derived from partially hydrolyzed wheat straw pulp by sulfation with chlorosulfonic acid in pyridine.EFFECT: agent of the invention is characterized by high antithrombotic and low hemorrhagic activity.1 tbl, 3 ex
Pharmacological composition on basis of iron compounds // 2625739
FIELD: pharmacology.SUBSTANCE: invention is a pharmacological composition containing the iron (II) sulphate for treatment of iron deficiency anemia, characterised in that it additionally contains iron hexacyanoferrate, iron-potassium hexacyanoferrate, potassium sulfate and micro cellulose, the components in the composition being in a certain ratio, in weight percent.EFFECT: high therapeutic efficacy, good tolerability, and low toxicity.2 cl, 5 ex
Pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol, method for its production and applications for cardiovascular diseases treatment // 2625039
FIELD: pharmacology.SUBSTANCE: pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol for cardiovascular diseases treatment contains a therapeutically effective amount of O-(4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]hept-exo-2-yl)benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1,4)-α-D-glucan (Dibornol-HEC) as an active ingredient. Sodium chloride, Tween 80, ascorbic acid, water for injection or saline in the amounts indicated in the claims are used as auxiliary components. In the method for pharmaceutical injection form preparation, the Dibornol-HEC substance is added to an aqueous solution of Tween 80 surfactant and mixed until the substance is dissolved completely and a clear solution is obtained, the water is distilled off under reduced pressure, ascorbic acid, sodium chloride, saline (water for injection) are added to the dry residue and mixed, the solution is adjusted to a concentration of 4.5-7.5% by the active Dibornol-HEC substance with saline (water for injection) and centrifuged, if necessary, the solution is filtered, the resulting drug solution is poured into glass vials or ampoules, which are sealed and packaged.EFFECT: pharmaceutical injection form of the invention is stable.2 cl, 1 tbl, 15 ex
ethod for diagnostics and rehabilitation of children of school age in iron-defective condition // 2624383
FIELD: medicine.SUBSTANCE: preliminary questioning is carried out and peripheral blood is taken with determination of hemoglobin level, colour index, ferritin, total iron binding ability of serum, serum iron. The results obtained are evaluated using a point system. If a colour index corresponding to the norm is revealed, serum iron level is 14-15 μmol/l, ferritin corresponds to the norm and the level of total iron binding capacity of the serum is less than 63 μmol/l, each indicator is assigned a point equal to 1 - iron deficiency degree coefficient K1, and the condition is concluded with its compliance with the state of prelatent iron deficiency. If the colour index is normal, serum iron is less than 14 μmol/l, ferritin is 10-11 μg/l, the total iron binding capacity of the serum is also less than 64-69 μmol/l, each indicator is assigned a point equial to 2 - K2, and condition compliance with the state of latent iron deficiency is concluded. With a hemoglobin decrease relative to the norm and colour index less than 86%, serum ironless than 12 μmol/L, ferritin less than 10 μg/l and the total iron binding capacity of 70 μmol/l and more, each indicator is assigned 3 points - K3, the state of iron deficiency anemia is concluded. Then the questionnaire is reviewed to identify symptoms such as weakness, fatigue, malaise, poor sleep, decreased concentration, physical development, paleness of skin and mucous membranes, dry skin and hair, layering and lateral pectoral nails, taste perversion, dizziness, headaches, angular stomatitis, shortness of breath at moderate and low physical activity, systolic murmur, clearly heard in the vessels. At that, each identified symptom is assigned 1 point - K4. The total ΣK value is then determined by the formula ΣK=K1+K2+K3+K4. If the total of points is 1-10, the schoolchild shall walk in the fresh air for at least 2 hours, eat meat products of not less than 120 g per day, an increased amount of fruits and vegetables, rich in iron, receive herbal infusions, oxygen cocktails, mineral adenous water. At ΣK equal to 11-20 points, multivitamin complexes courses and homeopathic ferrin drug at a dose of 5 granules under the tongue until complete resorption 3 times a day for 2-3 months are added to the above mentioned prescriptions also without missing classes. When ΣK above 20 points, the treatment course includes the scheme provided for schoolchildren with prelatent iron deficiency in combination with the introduction of medicinal iron-containing drugs prescribed by the paediatrician in outpatient or inpatient settings.EFFECT: increased accuracy and simplification of early preclinical diagnostics of early stages of iron deficiency, increased efficiency of rehabilitation of patients with iron deficiency.3 tbl, 3 ex
ethod for preparation and application of autological erythrocytes from umbilical blood for anemia correction in newborns // 2624253
FIELD: medicine.SUBSTANCE: method includes the following steps: umbilical cord samples collection, processing, placement for storage and rejection of samples, a pre-transfusion processing for umbilical blood samples. At the pretransfusion preparation stage, the erythrocyte mass from the plasma is separated by centrifugation at acceleration of 3768 g for 15 minutes at a temperature of +4°C. Then the auto-erythromass samples pass the procedure of auto-erythrocytes washing from the preservative and hemolyzed cells formed during umbilical cord sample storage. To do this, 100 ml of sterile physiological sodium chloride solution is added to the packet with auto-erythromass in the umbilical erythromass and physiological solution ratio of 1:1 and centrifuged at 1971 g acceleration for 10 minutes at a temperature of +4°. After this, the supernatant is removed using a plasma extractor. The washed umbilical erythrocytes are filtered through a microaggregate filter. All samples of autologous erythrocytes of umbilical blood pass quality control: the degree of hemolysis and quantitative indicators of blood cells, hemoglobin and hematocrit are determined.EFFECT: invention allows to correct anemia in newborns by a single blood transfusion, without occurrence of posttransfusion complications associated with donor blood components transfusion.11 tbl, 3 ex
Pharmaceutical composition for hyperlipidemia treatment // 2623876
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for hyperlipidemia treatment comprises a mixture of a glycyrrhizic derivative selected from glycyrrhizic acid and a pharmaceutically acceptable salt thereof, and a hypolipidemic drug-statin selected from atorvastatin, lovastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin, fluvastatin and pharmaceutically acceptable salts or mixtures thereof, and auxiliary substances.EFFECT: increased efficiency of the composition application.24 cl, 36 tbl, 2 ex
1-substituted-3-{[2-(3,5-di-tret-4-hydroxyphenyl)-2-oxoethyl]}-2aminobenzimidazolium bromides with antiplatelet and antioxidant properties // 2623439
FIELD: pharmacology.SUBSTANCE: invention relates to new benzimidazole derivatives of the general formula I , where (Ia) R = n-propyl, (Ib) R = allyl, which has antiplatelet and antioxidant properties.EFFECT: new benzimidazole derivatives are obtained, useful for myocardial infarction and stroke treatment.2 tbl, 2 ex
Treatment-and-prophylactic chelate iron containing drug for farm animals // 2623071
FIELD: veterinary medicine.SUBSTANCE: treatment-and-prophylactic chelate iron-containing drug for farm animals, includes iron gluconate, with III valency, vitamins B12, B3 and water at the following component ratio, wt %: iron gluconate (III) 20.0-80.0, vitamin B12 1.5-5.0, vitamin B3 1.5-10.0, water for injection - the rest.EFFECT: use of the claimed invention allows to compensate and prevent the iron deficiency of farm animals, to increase immunity, improve the growth and development of animals.4 tbl, 4 ex

Application of recombinant strain of bacillus subtilis eo-11 rncim b-11978 as the product of subtitlisin-like proteinase, substances with thrombolytic and anticoagulant properties // 2622006
FIELD: biotechnology.SUBSTANCE: invention can be used for lysis (dissolution) of blood clots formed in the blood vessels (thrombus) that disrupt normal blood circulation and threaten life, and prevention of blood clots formation. This is achieved by using the product of vital activity of recombinant strain Bacillus subtilis EO-11 RNCIM B-11978 - subtilisin-like proteinase - a substance with thrombolytic and anticoagulant properties.EFFECT: increasing the effectiveness of thrombus lysis, accelerating the process of thrombolysis without adverse side effects, preventing thrombus formation in the circulatory system of organisms, increasing the effectiveness and quality of treatment.3 cl, 3 dwg
ethod // 2621681
FIELD: chemistry.SUBSTANCE: invention relates to a new method for preparation of a tri (hydroxypyrone) trivalent ferric compound, comprising hydroxypyrone reaction with non-carboxylated ferric salt in an aqueous solution and tri (hydroxypyrone) trivalent ferric compound precipitation from an aqueous solution with pH greater than 7, wherein hydroxypyrone is in an aqueous solution containing a base to which a non-carboxylated salt is added, or wherein hydroxypyrone is added to water, the water is heated, non-carboxylated salt is added to the heated water, and the resulting solution is combined with an aqueous alkaline solution containing hydroxypyrone, and wherein hydroxypyrone is selected from maltol, ethylmaltol and mixtures thereof.EFFECT: method eliminates organic solvents application, or eliminates previously existing impurities, or increases the yield of ferric iron and hydroxypyrone compound, or reduces the total amount of solvent required for the reaction.13 cl, 4 ex
Energometabolic composition for preventive therapy of metabolic acidosis, ketosis, and iodine deficiency in cows // 2620557
FIELD: agriculture.SUBSTANCE: claimed energometabolic composition for preventive therapy contains beet molasses, succinic acid and citric acid, sodium chloride, iodinol in aqueous solution in the following ratio, wt %: succinic acid - 1,5, citric acid - 0,15, beet molasses - 50, sodium chloride - 2,5, iodinol - 5,0, water - the rest The claimed method involves the use of the claimed composition with the multiplicity of once in 5-7 days by watering animals at a dilution of the composition in water of 1:5-7 or mixing it with the fodder.EFFECT: group of inventions relates to the field of veterinary medicine and is intended for the prevention of metabolic acidosis, ketosis, and hypothyroidism in cows.2 cl, 4 tbl, 1 ex

Derivatives of blood coagulation factors vii and viia, conjugates and complexes containing them and their application // 2620072
FIELD: biotechnology.SUBSTANCE: invention relates to production of blood coagulation derivatives VII and VIIa, their conjugates with polymers capable of increasing the half-life of blood from the bloodstream, complexes containing them obtained by carrier binding to the conjugate, to genes encoding the derivatives, to expression vectors containing these genes, transformants with introduced expression vectors, to methods for their preparation, pharmaceutical compositions and treatment methods, and can be used in medicine to prevent or treat hemophilia or to improve blood coagulation. A FVII derivative is obtained which is linked at its C-terminus to the peptide linker for binding to a non-peptidyl polymer capable of increasing the half-life of FVII or FVIIa from the blood stream. At that, the peptide linker is a partial sequence of superoxide dismutase SOD1, its mutated sequence or GGGGSC sequence.EFFECT: invention allows to obtain an FVII derivative capable of binding to a carrier increasing the half-life from the blood stream while maintaining FVII activity.42 cl, 8 dwg, 3 tbl, 8 ex

ultispecific antigen-binding molecule with alternate function to blood coagulation factor viii function // 2620071
FIELD: biotechnology.SUBSTANCE: invention relates to a bispecific antibody that binds to both blood coagulation factor IX/activated blood coagulation factor IX, and blood coagulation factor X, and functionally replaces blood coagulation factor VIII. This invention discloses the nucleic acid encoding the said bispecific antibody, a vector, a cell and a method for antibody production, as well as a pharmaceutical composition and a kit for use in the method for prevention and/or treatment of bleeding or diseases associated with or caused by bleeding.EFFECT: invention may find further application for treatment of diseases associated with impaired blood clotting, such as acquired hemophilia and von Willebrand disease.17 cl, 6 dwg, 2 ex
Agents with diuretic activity // 2619350
FIELD: pharmacology.SUBSTANCE: diuretic contains 0.5% solution of humic acids and magnesium chloride, taken in a certain ratio.EFFECT: means allows to increase therapy effectiveness and eliminates occurrence of side effects.3 ex
Agent with diuretic activity // 2619349
FIELD: pharmacology.SUBSTANCE: diuretic contains 0.5% solution of humic acids and zinc chloride, taken in a certain ratio.EFFECT: means allows to increase therapy effectiveness and eliminates occurrence of side effects.3 ex
 
2550856.
Up!